- Home
- MCRB vs ZTEK Comparison
MCRB vs ZTEK Comparison
Compare MCRB & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | ZTEK |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 59.5M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MCRB | ZTEK |
|---|---|---|
| Price | $4.65 | $0.55 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 97.6K | ★ 137.6K |
| Earning Date | 05-11-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $789,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.59 | $0.37 |
| 52 Week High | $29.98 | $1.24 |
Technical Indicators
Market Signals| Indicator | MCRB | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 58.73 |
| Support Level | N/A | $0.55 |
| Resistance Level | $9.53 | $0.56 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 7.31 | 69.63 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About ZTEK Zentek Ltd.
Zentek Ltd is engaged in developing opportunities in the graphene and related nano-materials industry based on its intellectual property, patents, and Albany graphite. The Company's operating segments are Intellectual Property Development, Biotech, and Albany Project. Intellectual Property Development includes the manufacturing and distribution of graphene-related products. Biotech includes service revenue generated through aptamer technology. The Albany Project includes the exploration and evaluation of assets and mineral exploration activities.